Cargando…
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
BACKGROUND: Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma i...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098839/ https://www.ncbi.nlm.nih.gov/pubmed/30147940 http://dx.doi.org/10.1186/s40661-018-0063-3 |